Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CYTK – Cytokinetics, Incorporated

Float Short %

12

Margin Of Safety %

Put/Call OI Ratio

0.21

EPS Next Q Diff

-0.05

EPS Last/This Y

-0.71

EPS This/Next Y

-0.01

Price

64.13

Target Price

79.56

Analyst Recom

1.52

Performance Q

24.52

Relative Volume

0.73

Beta

0.55

Ticker: CYTK




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-10CYTK62.220.190.05114212
2025-11-11CYTK66.790.191.57114236
2025-11-12CYTK660.210.40116445
2025-11-13CYTK65.520.211.12118243
2025-11-14CYTK66.390.221.62119045
2025-11-17CYTK66.970.210.13119103
2025-11-18CYTK66.140.210.28119649
2025-11-19CYTK64.750.210.21119725
2025-11-20CYTK62.910.210.33119707
2025-11-21CYTK65.40.220.42120223
2025-11-24CYTK67.180.160.37104785
2025-11-25CYTK67.520.160.43105912
2025-11-26CYTK68.190.160.14106114
2025-12-01CYTK66.10.210.18110868
2025-12-02CYTK63.580.211.04111552
2025-12-03CYTK64.70.210.01111732
2025-12-04CYTK66.820.210.02111454
2025-12-05CYTK65.720.210.52111564
2025-12-08CYTK64.120.211.08112127
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-10CYTK62.20-9.315.8-5.62
2025-11-11CYTK66.50-9.3-24.4-5.87
2025-11-12CYTK66.04-9.322.1-5.87
2025-11-13CYTK65.50-7.522.2-5.92
2025-11-14CYTK66.40-7.59.7-5.92
2025-11-17CYTK66.97-9.513.0-6.10
2025-11-18CYTK66.15-9.525.7-5.89
2025-11-19CYTK64.79-9.530.8-5.89
2025-11-20CYTK63.55-8.729.6-5.95
2025-11-21CYTK65.41-5.6-0.6-5.96
2025-11-24CYTK67.21-5.61.2-5.96
2025-11-25CYTK67.55-5.614.8-5.96
2025-11-26CYTK68.16-5.612.4-5.96
2025-12-01CYTK66.06-5.636.8-5.96
2025-12-02CYTK63.51-5.642.4-5.96
2025-12-03CYTK64.66-5.66.8-5.96
2025-12-04CYTK66.56-5.6-0.2-5.96
2025-12-05CYTK65.67-7.226.1-5.97
2025-12-08CYTK64.13-7.2- -5.97
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-10CYTK-4.481.5311.87
2025-11-11CYTK-4.481.5311.87
2025-11-12CYTK-4.481.5311.53
2025-11-13CYTK-4.651.5311.53
2025-11-14CYTK-4.651.5311.52
2025-11-17CYTK-4.497.7111.52
2025-11-18CYTK-4.577.7111.52
2025-11-19CYTK-4.577.7111.52
2025-11-20CYTK-4.747.7111.52
2025-11-21CYTK-4.677.7111.50
2025-11-24CYTK-5.053.7811.50
2025-11-25CYTK-5.053.7811.50
2025-11-26CYTK-5.053.7812.00
2025-12-01CYTK-5.053.7412.00
2025-12-02CYTK-6.383.7412.00
2025-12-03CYTK-6.383.7412.00
2025-12-04CYTK-6.313.7412.00
2025-12-05CYTK-6.313.7412.00
2025-12-08CYTK-7.743.6612.00
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-1.54

Avg. EPS Est. Current Quarter

-1.35

Avg. EPS Est. Next Quarter

-1.59

Insider Transactions

-7.74

Institutional Transactions

3.66

Beta

0.55

Average Sales Estimate Current Quarter

10

Average Sales Estimate Next Quarter

19

Fair Value

Quality Score

8

Growth Score

40

Sentiment Score

20

Actual DrawDown %

41.8

Max Drawdown 5-Year %

-72.4

Target Price

79.56

P/E

Forward P/E

PEG

P/S

89.91

P/B

P/Free Cash Flow

EPS

-6.31

Average EPS Est. Cur. Y​

-5.97

EPS Next Y. (Est.)

-5.98

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-862.21

Relative Volume

0.73

Return on Equity vs Sector %

117.4

Return on Equity vs Industry %

132.3

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.36

EBIT Estimation

Cytokinetics, Incorporated
Sector: Healthcare
Industry: Biotechnology
Employees: 498
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
stock quote shares CYTK – Cytokinetics, Incorporated Stock Price stock today
news today CYTK – Cytokinetics, Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch CYTK – Cytokinetics, Incorporated yahoo finance google finance
stock history CYTK – Cytokinetics, Incorporated invest stock market
stock prices CYTK premarket after hours
ticker CYTK fair value insiders trading